Dr Graham Dark
| Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal cancer treatment (ICON8): overall survival results from an open-label, randomised, controlled, phase 3 trial | 2022 |
|
Dr Graham Dark
| Objective responses to first-line neoadjuvant carboplatin–paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trial | 2021 |
|
Dr Graham Dark
| Weekly platinum-based chemotherapy versus 3-weekly platinum-based chemotherapy for newly diagnosed ovarian cancer (ICON8): quality-of-life results of a phase 3, randomised, controlled trial | 2020 |
|
Dr Graham Dark
| An international, phase III randomized trial in patients with mucinous epithelial ovarian cancer (mEOC/GOG 0241) with long-term follow-up: and experience of conducting a clinical trial in a rare gynecological tumor | 2019 |
|
Dr Graham Dark
| Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial | 2019 |
|
Dr Graham Dark
| Impact of a 2-Week Oncology Placement on Medical Students’ Perception of Cancer | 2018 |
|
Dr Graham Dark
Professor Roderick Skinner
| An Association of Cancer Physicians' strategy for improving services and outcomes for cancer patients | 2016 |
|
Dr Graham Dark
| Single-agent pemetrexed for chemonaive and pretreated patients with malignant pleural mesothelioma - Results of an International Expanded Access Program | 2008 |
|
Dr Graham Dark
Rebecca Perrett
| Deconstructing the construction of a learning module on practice development | 2007 |
|
Dr Graham Dark
| Developing a web-based multidisciplinary cancer education forum | 2007 |
|
Dr Graham Dark
| Evaluation of oral versus intravenous dose of vinorelbine to achieve equivalent blood exposures in patients with solid tumours | 2007 |
|
Dr Graham Dark
| Open-label study of pemetrexed alone or in combination with a platinum for previously treated patients (pts) with malignant pleural mesothelioma (MPM): Outcomes from the International Expanded Access Program (EAP) | 2007 |
|
Dr Graham Dark
| Phase II study of vinflunine in malignant pleural mesothelioma | 2007 |
|
Dr Graham Dark
Rebecca Perrett
| Practice development - Part 1: Developing a practice initiative in oncology and palliative care | 2007 |
|
Dr Graham Dark
Rebecca Perrett
| Practice development - Part 2: evaluating a practice initiative | 2007 |
|
